Board of directors
Gemma Voss, PhD
Chief Executive Officer
Gemma Voss has a MSc degree in Health Science and completed her PhD thesis “Severity of illness and cost of medical care in patients with Acute Myocardial infarction” at the Maastricht University in The Netherlands.
Gemma has more than 20 years of experience in implementing, supervising and supporting various Clinical Trials with a specialization in economic evaluation studies. Before joining Cardialysis, she was CEO of the Clinical Trial Center Maastricht BV (CTCM) for over 10 years. This company from the Maastricht University Medical Center has been set up by her and has grown under her leadership into a leading Academic Research Organization in the Netherlands. Gemma is the representative of the Board of Cardialysis and heads the Management Team.
Ron van Amsterdam, PhD, DipPharMed
Director of Business Development
Ron van Amsterdam joined Cardialysis in 2019 after a well-rounded professional career in Pharma. Ron moved from a pharmacologist (PhD, Groningen-NL), medical scientist (Diplome of Pharmaceutical Medicine, Surrey-UK) into resource management (Lean Six sigma Green Belt, Leiden NL). After over 25 years in pharma industry (at Organon, Pharming and Astellas in chronic inflammation, thrombosis, and anti-infectives) currently, Ron is a member of the Management Team of Cardialysis and develops new business strategies around their scientific service opportunities while ensuring continued marketing and sales activities.
Prior to joining Cardialysis, Ron assumed increasingly senior leadership roles in pharmacology, clinical pharmacology, medical science and clinical operations, published scientific papers, as well as inventions, and consulted in multiple drug registrations at CHMP and FDA. His latest job since 2009, involved resource management for global drug development project management, program management in Nephrology and Urology, multiple improvement initiatives around Astellas’ R&D process and Organizational structure (closely working with US and Japanese peers), and facility management in The Netherlands.
Ernest Spitzer, MD
Dr. Ernest Spitzer is a cardiologist trained in Zaragoza, Spain, with focus on cardiovascular research. Before joining Cardialysis in 2014, he completed advanced training in cardiovascular imaging in Vienna, Austria, and a research fellowship in interventional cardiology in Bern, Switzerland. Since February 2020, Dr. Spitzer is Medical Director at Cardialysis, ensuring medical and clinical trial expertise in processes such as endpoint adjudication, data and safety monitoring boards, medical monitoring, safety reporting, trial design, and core lab processes, in close collaboration with operational and scientific experts.
Dr. Spitzer graduated summa cum laude in 2015 from the Catholic University of Saint Mary, Arequipa, Peru, and served two years at the Peruvian Armed Forces. He completed his cardiology training at the University Hospital Miguel Servet, Zaragoza, Spain. He has been recognized with a research fellowship from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology and a research fellowship from the Spanish Society of Cardiology. In 2014, he completed a 4-year master program in statistics and research methodology at the Autonomous University of Barcelona. He has contributed with 50+ articles in peer-reviewed journals and is Board Member of the Academic Research Consortium since March 2019.
Goran Rudez, PhD
Director of Innovation and Quality
Goran Rudez is working for Cardialysis since 2010 and has been active within the company in various roles, ranging from business development towards operational excellence. His current position as the Director of Innovation and Quality focusses on the Cardialysis’ processes and computerized systems seeking a best-fit for the current market while remaining efficient and compliant.
Prior to joining Cardialysis, Goran has worked over 10 years as a biomedical scientist mainly within the cardiovascular research area. During this period he has obtained his PhD at the Erasmus Medical Center in Rotterdam, the Netherlands in 2009 with the thesis “Role of P2RY12 Gene Variants and Biological Variation in Arterial Thrombosis”.
Director Finance & Legal Affairs
During his almost 30 years tenure at Cardialysis, Frits Kesselring has taken many responsibilities that enabled the transformation from a locally oriented Core Lab spun off from the Erasmus Medical Center into the professional and global company it is today. Perhaps most impactful was his key role in setting up the current corporate Group structure, including ECRI, and roll-out of the first major ECRI project, GLOBAL LEADERS. At some point, when the facilities needed fundamental restructuring in order to enhance visibility and connect all co-workers thus far spread over two floors, Frits took project leadership turning a large empty concrete 2600-sqm 6th floor at the Westblaak Rotterdam into a state-of-the-art facility integrating fit-for-purpose the intimacy of personal spaces with interactive open offices with maximum daylight.
Born in Rotterdam, his no-nonsense, loyal and dedicated attitude just makes things happen. As an explicit supporter of ‘his’ soccer team Sparta, Frits is collaborative and goal-oriented and over the years, he moved from the precise junior accountant of middle-sized companies like Cardialysis, when he just joined from PriceWaterhouseCoopers, into the more visionary financial leader Cardialysis enjoys today: critical, analytic, yet still helpul and no-nonsense; trusted and reliable when it comes to achieving a fair deal in his current position.